Advertisement

Involvement of κ-Opioid and Endocannabinoid System on Salvinorin A-Induced Reward

      Background

      The recreational drug, Salvinorin A, derived from the plant of Salvia divinorum, is a potent and selective κ-opioid receptor agonist. The abuse of selective k-agonists is a novel phenomenon, the mechanism of which is not fully understood.

      Methods

      We investigated salvinorin A given SC on the conditioned place preference (.05–160 μg/kg) and intracerebroventricular (ICV) self-administration (.01–1 μg/infusion) paradigms, in Wistar rats.

      Results

      The present results demonstrate the rewarding effects of Salvinorin A in a range of doses between .1 and 40 μg/kg SC for conditioned place preference test and .1–.5 μg/infusion for ICV self-administration. Highest doses (160 μg/kg for conditioned place preference test and 1 μg/infusion for ICV self-administration) were aversive. The rewarding effect was antagonized by intraperitoneal (IP) pretreatment with the cannabinoid CB1 receptor antagonist, rimonabant [N-piperidino-5-(4-chlorophenyl)1-(2,4-dichloro phenyl)-4 methyl pyrazole 3-carboxamide] (1 mg/kg), and the κ-opioid receptor antagonist, nor-binaltorphimine (nor-BNI) (10 mg/kg). In the shell of nucleus accumbens, dopamine extracellular levels were increased after administration of salvinorin A (40 μg/kg SC), reaching a maximum value of about 150%.

      Conclusions

      These data provide the demonstration of the rewarding effects of Salvinorin A through an interaction between κ-opioid and (endo)cannabinoid system in rats.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Roth B.L.
        • Baner K.
        • Westkaemper R.
        • Siebert D.
        • Rice K.C.
        • Steinberg S.
        • et al.
        Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist.
        Proc Natl Acad Sci U S A. 2002; 99: 11934-11939
        • Sheffler D.J.
        • Roth B.L.
        Salvinorin A: The “magic mint” hallucinogen finds a molecular target in the kappa opioid receptor.
        Trends Pharmacol Sci. 2003; 24: 107-109
        • Chavkin C.
        • Sud S.
        • Jin W.
        • Stewart J.
        • Zjawiony J.K.
        • Siebert D.J.
        • et al.
        Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.
        J Pharmacol Exp Ther. 2004; 308: 1197-1203
        • Yan F.
        • Roth B.L.
        Salvinorin A: A novel and highly selective kappa-opioid receptor agonist.
        Life Sci. 2004; 75: 2615-2619
        • Prisinzano T.E.
        Psychopharmacology of the hallucinogenic sage Salvia divinorum.
        Life Sci. 2005; 78: 527-531
        • Siebert D.J.
        Salvia divinorum and salvinorin A: New pharmacologic findings.
        J Ethnopharmacol. 1994; 43: 53-56
        • Gonzalez D.
        • Riba J.
        • Bouso J.C.
        • Gomez-Jarabo G.
        • Barbanoj M.J.
        Pattern of use and subjective effects of Salvia divinorum among recreational users.
        Drug Alcohol Depend. 2006; 85: 157-162
        • Turner D.M.
        Salvinorin: The Psychedelic Essence of Salvia Divinorum.
        Panther Press, San Francisco1996
        • Rothman R.B.
        • Murphy D.L.
        • Xu H.
        • Godin J.A.
        • Dersch C.M.
        • Partilla J.S.
        • et al.
        Salvinorin a: Allosteric interactions at the mu opioid receptor.
        J Pharmacol Exp Ther. 2007; 320: 801-810
        • Capasso R.
        • Borrelli F.
        • Capasso F.
        • Siebert D.J.
        • Stewart D.J.
        • Zjawiony J.K.
        • et al.
        The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum.
        Neurogastroenterol Motil. 2006; 18: 69-75
        • Mowry M.
        • Mosher M.
        • Briner W.
        Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A.
        J Psychoactive Drugs. 2003; 35: 379-382
        • McCurdy C.R.
        • Sufka K.J.
        • Smith G.H.
        • Warnick J.E.
        • Nieto M.J.
        Antinociceptive profile of salvinorin A, a structurally uniquekappa opioid receptor agonist.
        Pharmacol Biochem Behav. 2006; 83: 109-113
        • Ansonoff M.A.
        • Zhang J.
        • Czyzyk T.
        • Rothman R.B.
        • Stewart J.
        • Xu H.
        • et al.
        Antinociceptive and hypothermic effects of salvinorin A are abolished in a novel strain of KOR-1 KO mice.
        J Pharmacol Exp Ther. 2006; 318: 641-648
        • Fantegrossi W.E.
        • Kugle K.M.
        • Valdes 3rd, L.J.
        • Koreeda M.
        • Woods J.H.
        Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse.
        Behav Pharmacol. 2005; 16: 627-633
        • Carlezon Jr., W.A.
        • Beguin C.
        • DiNieri J.A.
        • Baumann M.H.
        • Richards M.R.
        • Todtenkopf M.S.
        • et al.
        Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats.
        J Pharmacol Exp Ther. 2006; 316: 440-447
        • Zhang Y.
        • Butelman E.R.
        • Schlussman S.D.
        • Ho A.
        • Kreek M.J.
        Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: Agonist actions at kappa opioid receptors.
        Psychopharmacology (Berl). 2005; 179: 551-558
        • Butelman E.R.
        • Harris T.J.
        • Kreek M.J.
        The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.
        Psychopharmacology (Berl). 2004; 172: 220-224
        • Mendizábal V.
        • Zimmer A.
        • Maldonado R.
        Involvement of κ/Dynorphin system in WIN 55,212-2 self-Administration in mice.
        Neuropsychopharmacology. 2006; 31: 1957-1966
        • Maldonado R.
        • Valverde O.
        • Berrendero F.
        Involvement of the endocannabinoid system in drug addiction.
        Trends Neurosci. 2006; 29: 225-232
        • Braida D.
        • Pozzi M.
        • Cavallini R.
        • Sala M.
        3,4 methylenedioxymethamphetamine (ecstasy) impairs eight-arm radial maze performance and arm entry pattern in rats.
        Behav Neurosci. 2002; 116: 298-304
        • Braida D.
        • Pozzi M.
        • Cavallini R.
        • Sala M.
        Conditioned place preference induced by the cannabinoid agonist CP 55,940: Interaction with the opioid system.
        Neuroscience. 2001; 104: 923-926
        • Braida D.
        • Virag W.
        • Ottonello F.
        • Inghilterra S.
        • Gori E.
        • Sala M.
        A novel method for self-administering addicting drugs intracerebroventricularly in a free-choice procedure.
        Brain Res Brain Res Protoc. 1998; 3: 135-141
        • Paxinos G.
        • Watson C.
        The Rat Brain in Stereotaxic Coordinates.
        Academic Press, New York1986
        • Bert L.
        • Favale D.
        • Jego G.
        • Greve P.
        • Guilloux J.P.
        • Guiard B.P.
        • et al.
        Rapid and precise method to locate microdialysis probe implantation in the rodent brain.
        J Neurosci Methods. 2004; 140: 53-57
        • Braida D.
        • Iosue S.
        • Pegorini S.
        • Sala M.
        Δ9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats.
        Eur J Pharmacol. 2005; 511: 75-76
        • Braida D.
        • Limonta V.
        • Pegorini S.
        • Zani A.
        • Guerini-Rocco C.
        • Gori E.
        • Sala M.
        Hallucinatory and rewarding effect of salvinorin A in zebrafish: κ-opioid and CB1-cannabinoid receptor involvement.
        Psychopharmacology. 2007; 190: 441-448
        • Valdes L.J.
        • Diaz J.L.
        • Paul A.G.
        Ethnopharmacology of ska Maria Pastora (Salvia divinorum).
        J Ethnopharmacol. 1983; 7: 287-312
        • Braida D.
        • Pozzi M.
        • Parolaro D.
        • Sala M.
        Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system.
        Eur J Pharmacol. 2001; 413: 227-234
        • Braida D.
        • Sala M.
        Role of the endocannabinoid system in MDMA intracerebral self-administration in rats.
        Br J Pharmacol. 2002; 136: 1089-1092
        • Koob G.F.
        The reward system and cocaine abuse.
        in: Korenman S.G. Barchas J.D. Biological Basis of Substance Abuse. Oxford Univ. Press, New York1993: 339-354
        • Shippenberg T.S.
        • Herz A.
        Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu-kappa-opioid agonists.
        Brain Res. 1987; 436: 169-172
        • Bals-Kubik R.
        • Herz A.
        • Shippenberg T.S.
        Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated.
        Psychopharmacology. 1989; 98: 203-206
        • Mori T.
        • Nomura M.
        • Nagase H.
        • Narita M.
        • Suzuki T.
        Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820 on the discriminative stimulus and rewarding effects of cocaine in rats.
        Psychopharmacology. 2002; 161: 17-22
        • Suzuki T.
        • Shiozaki Y.
        • Masukawa Y.
        • Misawa M.
        • Nagase H.
        The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference.
        Jpn J Pharmacol. 1992; 58: 435-442
        • Iwamoto E.T.
        Characterization of dynorphin A(1-17)-induced place preference in rats.
        NIDA Res Monogr. 1989; 95: 308-309
        • Marinelli M.
        • Barrot M.
        • Simon H.
        • Oberlander C.
        • Dekeyne A.
        • Le Moal M.
        • Piazza P.V.
        Pharmacological stimuli decreasing nucleus accumbens dopamine can act as positive reinforcers but have a low addictive potential.
        Eur J Neurosci. 1998; 10: 3269-3275
        • Bellissant E.
        • Denolle T.
        • Sinnassamy P.
        • Bichet D.G.
        • Giudicelli J.F.
        • Lecoz F.
        • et al.
        Systemic and regional hemodynamic and biological effects of a new kappa-opioid agonist, niravoline, in healthy volunteers.
        J Pharmacol Exp Ther. 1996; 278: 232-242
        • McLaughlin J.P.
        • Land B.B.
        • Li S.
        • Pintar J.E.
        • Chavkin C.
        Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning.
        Neuropsychopharmacology. 2006; 31: 787-799
        • Wang Y.
        • Tang K.
        • Inan S.
        • Siebert D.
        • Holzgrabe U.
        • Lee D.
        • et al.
        Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.
        J Pharmacol Exp Ther. 2005; 312: 220-230
        • Hanes K.R.
        Antidepressant effects of the herb Salvia divinorum: A case report.
        J Clin Psychopharmacol. 2001; 21: 634-635
        • Heimer L.
        • Zahm D.S.
        • Churchill L.
        • Kalivas P.W.
        • Wohltmann C.
        Specificity in the projection patterns of accumbal core and shell in the rat.
        Neuroscience. 1991; 41: 89-125
        • Di Chiara G.
        A motivational learning hypothesis of the role of dopamine in compulsive drug use.
        J Psychopharmacol. 1998; 12: 54-67
        • Di Chiara G.
        Drug addiction as dopamine-dependent associative learning disorder.
        Eur J Pharmacol. 1999; 375: 13-30
        • Sandi C.
        • Borrell J.
        • Guaza C.
        Involvement of kappa type opioids on ethanol drinking.
        Life Sci. 1988; 42: 1067-1075
        • Funada M.
        • Suzuki T.
        • Narita M.
        • Misawa M.
        • Nagase H.
        Blockade of morphine reward through the activation of kappa-opioid receptors in mice.
        Neuropharmacology. 1993; 32: 1315-1323
        • Glick S.D.
        • Maisonneuve I.M.
        • Raucci J.
        • Archer S.
        Kappa opioid inhibition of morphine and cocaine self-administration in rats.
        Brain Res. 1995; 681: 147-152
        • Hahn B.
        • Stolerman I.P.
        • Shoaib M.
        Kappa-opioid receptor modulation of nicotine-induced behaviour.
        Neuropharmacology. 2000; 39: 2848-2855